Case Report
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Mar 27, 2023; 15(3): 480-487
Published online Mar 27, 2023. doi: 10.4240/wjgs.v15.i3.480
Table 1 Overall health parameters during treatments records
Time
April, 2020
September, 2021
January, 2021
November, 2021
December, 2021
January, 2022
February, 2022
March, 2022
April, 2022
May, 2022
June, 2022
July, 2022
August, 2022
September, 2022
TreatmentAdmissionSuspend4 cycles of doxorubicin and carboplatin9 cycles of sindilizumb in combination with doxorubicin and carboplatin
Temp/°C37.1NA36.23736.536.836.536.337.136.8NA36.836.937.236.9
HR/min86NA7684757982788281NA79757977
RR/min19NA1918191919181917NA18191819
BP/kPa16.1/7.5NA15.4/8.518.7/9.718.4/11.116.9/11.916.5/9.316.5/9.716.0/9.514.0/8.4NA12.0/8.012.5/8.713.2/9.613.1/8.0
Weight/kg56NA495151.55253.85251.350.9NA50.55152.353
WBC/109/L5.11NA5.45.915.033.63.342.913.234.02NA4.424.514.434.52
Hb/g/L133NA12411410596102102106109NA111112112113
Alb/g/L39.9NA38.54240.336.945.6NA44.243.4NA43.140.737.635.3
ALT/U/L34NA2017171620212223NA24364754
AST/U/L29NA2524178.326NA2728NA28374347
CEA/µg/L1NA0.81.21.10.910.80.90.8NA0.80.90.80.8
CA125/U/mL11.1NA14.419.314.68.910.210.39.79.1NA99.39.710.7
CA199/U/mL71.2NA146.8151.5153.6154.3160.837.832.629.8NA22.324.325.627.1
CA153/U/mL4.9NA5.611.19.47.38.496.15.2NA4.64.64.54.5
CA724/U/mL2.3NA2.75.78.514.31.55.63.43.8NA2.42.32.22.1
Table 2 Laboratory examinations of the patient after two months of follow-up
Time
Temp/°C
HR/min
RR/min
BP/kPa
Weight/kg
WBC/109/L
Hb/g/L
Alb/g/L
ALT/U/L
AST/U/L
CEA/µg/L
CA125/U/mL
CA199/U/mL
CA153/U/mL
CA724/U/mL
January, 202236.5921714.2/9.644.75.9911843.119172.8322313.618.3
November, 202237871914.7/10.445.26.4511535.818232.331.724.615.619.3